Evidence map›Paper›PMID 34727233›Full record

ReviewNano convergence2021

Cancer nanotechnology: current status and perspectives.

Jessica A Kemp, Young Jik Kwon

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nano convergence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Advances in applications of siRNA in cancer therapy: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Development of Water-Dispersible CuS Nanoparticles for Chemo-Photothermal Therapy and Photoacoustic Application.Chemphyschem : a European journal of chemical physics and physical chemistry · 2025
    Article
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jessica A KempDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, CA, 92697, USA.
Young Jik KwonDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University of California, Irvine, CA, 92697, USA. kwonyj@uci.edu.ORCID http://orcid.org/0000-0003-4086-6995

Funding

Preclinical Validation of Dual-Modal Nanotherapy for Chronic Myeloid Neoplasms and BeyondR21CA228099 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KWON, YOUNG JIK · 2019 to 2020
$351k
NCI NIH HHS R21 CA228099NIH HHS 1R21CA228099-01A1
6 · The paper itself

Abstract

Modern medicine has been waging a war on cancer for nearly a century with no tangible end in sight. Cancer treatments have significantly progressed, but the need to increase specificity and decrease systemic toxicities remains. Early diagnosis holds a key to improving prognostic outlook and patient quality of life, and diagnostic tools are on the cusp of a technological revolution. Nanotechnology has steadily expanded into the reaches of cancer chemotherapy, radiotherapy, diagnostics, and imaging, demonstrating the capacity to augment each and advance patient care. Nanomaterials provide an abundance of versatility, functionality, and applications to engineer specifically targeted cancer medicine, accurate early-detection devices, robust imaging modalities, and enhanced radiotherapy adjuvants. This review provides insights into the current clinical and pre-clinical nanotechnological applications for cancer drug therapy, diagnostics, imaging, and radiation therapy.

Indexed as

CancerClinical translationDiagnosticsNanomedicineRadiationTheranostics

Identifiers

PMID34727233
PMCPMC8560887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.